Stock Events

Stock Events

Catalyst Biosciences 

0
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Jan 23
€3.32
Sep 22
€21.82
Aug 15
€7.57
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

18NovExpected
Q1 2026
Q2 2026
Next
-0.1
-0.09
-0.07
-0.05
Expected EPS
-0.10042695360000001
Actual EPS
N/A

Financials

4.44%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
100.84MRevenue
4.48MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HGF2.STU. It's not an investment recommendation.
Apple
2
AAPL
Microsoft
2
MSFT
Tesla
2
TSLA
Broadcom
2
AVGO

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals is a competitor because it also focuses on developing treatments for genetic diseases, similar to Gyre Therapeutics' focus on gene therapy.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is in the competition due to its leading role in CRISPR-Cas9 gene editing, a technology that could be used in similar applications as Gyre's gene therapy platform.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical targets rare genetic diseases with its enzyme replacement and gene therapy products, competing in the same niche as Gyre.
Intellia Therapeutics
NTLA
Mkt Cap1.8B
Intellia Therapeutics is a competitor because of its focus on CRISPR gene editing for the treatment of genetic diseases, directly competing with Gyre's gene therapy approach.
Editas Medicine
EDIT
Mkt Cap485.31M
Editas Medicine operates in the gene editing field, making it a competitor to Gyre Therapeutics by developing CRISPR-based therapies for genetic conditions.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals competes with Gyre by focusing on RNA interference (RNAi) for the treatment of genetic diseases, offering an alternative approach to gene therapy.
Ionis Pharmaceuticals
IONS
Mkt Cap10.15B
Ionis Pharmaceuticals is a competitor due to its work on RNA-targeted drug discovery and development, which could be used for similar therapeutic targets as Gyre's.
Sarepta Therapeutics
SRPT
Mkt Cap2.2B
Sarepta Therapeutics is involved in the development of RNA-based and gene therapy treatments for rare genetic diseases, directly competing with Gyre Therapeutics in the gene therapy space.

About

Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
Show more...
CEO
Ying Luo
Employees
618
Country
United States
ISIN
US14888D2080
WKN
000A3EE5F

Listings

STU
DE
L9S.STU
STU
DE
HGF2.STU
MU
DE
L9S.MU
XNAS
US
GYRE

0 Comments

Share your thoughts

FAQ

What is Catalyst Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Catalyst Biosciences stocks are traded under the ticker HGF2.STU.
When is the next Catalyst Biosciences earnings date?▼
Catalyst Biosciences is going to release the next earnings report on November 18, 2026.
What were Catalyst Biosciences earnings last quarter?▼
HGF2.STU earnings for the last quarter are -0.1 EUR per share, whereas the estimation was -0.05 EUR resulting in a -111.76% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Catalyst Biosciences revenue for the last year?▼
Catalyst Biosciences revenue for the last year amounts to 100.84M EUR.
What is Catalyst Biosciences net income for the last year?▼
HGF2.STU net income for the last year is 4.48M EUR.
Does Catalyst Biosciences pay dividends?▼
Yes, HGF2.STU dividends are paid quarterly. The last dividend per share was 3.32 EUR. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Catalyst Biosciences have?▼
As of September 05, 2026, the company has 618 employees.
In which sector is Catalyst Biosciences located?▼
Catalyst Biosciences operates in the Health & Wellness sector.
When did Catalyst Biosciences complete a stock split?▼
The last stock split for Catalyst Biosciences was on October 31, 2023 with a ratio of 1:15.
Where is Catalyst Biosciences headquartered?▼
Catalyst Biosciences is headquartered in SAN DIEGO, United States.